|
1.Bubeck, D., D. J. Filman, N. Cheng, A. C. Steven, J. M. Hogle, and D. M. Belnap. 2005. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol 79:7745-55. 2.Chang, C. S., Y. T. Lin, S. R. Shih, C. C. Lee, Y. C. Lee, C. L. Tai, S. N. Tseng, and J. H. Chern. 2005. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. J Med Chem 48:3522-35. 3.Chern, J. H., C. S. Chang, C. L. Tai, Y. C. Lee, C. C. Lee, I. J. Kang, C. Y. Lee, and S. R. Shih. 2005. Synthesis and antipicornavirus activity of (R)- and (S)-1-[5-(4'-chlorobiphenyl-4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidaz olidin-2-one. Bioorg Med Chem Lett 15:4206-11. 4.Dove, A. W., and V. R. Racaniello. 2000. An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures. J Virol 74:3929-31. 5.Filman, D. J., R. Syed, M. Chow, A. J. Macadam, P. D. Minor, and J. M. Hogle. 1989. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. Embo J 8:1567-79. 6.Fox, M. P., M. J. Otto, and M. A. McKinlay. 1986. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother 30:110-6. 7.Fricks, C. E., and J. M. Hogle. 1990. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol 64:1934-45. 8.Genovese, D., S. Catone, M. E. Farah, A. Gambacorta, and L. Fiore. 1999. Isolation and biological characterization of 3(2H)-isoflavene-resistant and -dependent poliovirus type 2 Sabin mutants. J Gen Virol 80 ( Pt 1):157-67. 9.Grant, R. A., C. N. Hiremath, D. J. Filman, R. Syed, K. Andries, and J. M. Hogle. 1994. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr Biol 4:784-97. 10.Hambidge, S. J., and P. Sarnow. 1992. Translational enhancement of the poliovirus 5' noncoding region mediated by virus-encoded polypeptide 2A. Proc Natl Acad Sci U S A 89:10272-6. 11.Ho, M., E. R. Chen, K. H. Hsu, S. J. Twu, K. T. Chen, S. F. Tsai, J. R. Wang, and S. R. Shih. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341:929-35. 12.Kaiser, L., C. E. Crump, and F. G. Hayden. 2000. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res 47:215-20. 13.Krenn, B. M., B. Holzer, E. Gaudernak, A. Triendl, F. J. van Kuppeveld, and J. Seipelt. 2005. Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions. J Virol 79:13892-9. 14.Lewis, J. K., B. Bothner, T. J. Smith, and G. Siuzdak. 1998. Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A 95:6774-8. 15.Liu, C. C., H. W. Tseng, S. M. Wang, J. R. Wang, and I. J. Su. 2000. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 17:23-30. 16.Mendelsohn, C. L., E. Wimmer, and V. R. Racaniello. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855-65. 17.Minor, P. D., G. C. Schild, J. Bootman, D. M. Evans, M. Ferguson, P. Reeve, M. Spitz, G. Stanway, A. J. Cann, R. Hauptmann, L. D. Clarke, R. C. Mountford, and J. W. Almond. 1983. Location and primary structure of a major antigenic site for poliovirus neutralization. Nature 301:674-9. 18.Mosser, A. G., and R. R. Rueckert. 1993. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J Virol 67:1246-54. 19.Muckelbauer, J. K., M. Kremer, I. Minor, G. Diana, F. J. Dutko, J. Groarke, D. C. Pevear, and M. G. Rossmann. 1995. The structure of coxsackievirus B3 at 3.5 A resolution. Structure 3:653-67. 20.Muckelbauer, J. K., M. Kremer, I. Minor, L. Tong, A. Zlotnick, J. E. Johnson, and M. G. Rossmann. 1995. Structure determination of coxsackievirus B3 to 3.5 A resolution. Acta Crystallogr D Biol Crystallogr 51:871-87. 21.Pevear, D. C., M. J. Fancher, P. J. Felock, M. G. Rossmann, M. S. Miller, G. Diana, A. M. Treasurywala, M. A. McKinlay, and F. J. Dutko. 1989. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol 63:2002-7. 22.Pevear, D. C., T. M. Tull, M. E. Seipel, and J. M. Groarke. 1999. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43:2109-15. 23.Rossmann, M. G. 1989. The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance. J Biol Chem 264:14587-90. 24.Rotbart, H. A. 2002. Treatment of picornavirus infections. Antiviral Res 53:83-98. 25.Rotbart, H. A., and A. D. Webster. 2001. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 32:228-35. 26.Salvati, A. L., A. De Dominicis, S. Tait, A. Canitano, A. Lahm, and L. Fiore. 2004. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus. Antimicrob Agents Chemother 48:2233-43. 27.Shia, K. S., W. T. Li, C. M. Chang, M. C. Hsu, J. H. Chern, M. K. Leong, S. N. Tseng, C. C. Lee, Y. C. Lee, S. J. Chen, K. C. Peng, H. Y. Tseng, Y. L. Chang, C. L. Tai, and S. R. Shih. 2002. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem 45:1644-55. 28.Shih, S. R., M. C. Tsai, S. N. Tseng, K. F. Won, K. S. Shia, W. T. Li, J. H. Chern, G. W. Chen, C. C. Lee, Y. C. Lee, K. C. Peng, and Y. S. Chao. 2004. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother 48:3523-9. 29.Si, X., B. M. McManus, J. Zhang, J. Yuan, C. Cheung, M. Esfandiarei, A. Suarez, A. Morgan, and H. Luo. 2005. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 79:8014-23. 30.Sivasamugham, L. A., M. J. Cardosa, W. S. Tan, and K. Yusoff. 2006. Recombinant newcastle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J Med Virol 78:1096-104. 31.Smyth, M., T. Pettitt, A. Symonds, and J. Martin. 2003. Identification of the pocket factors in a picornavirus. Arch Virol 148:1225-33. 32.Tsang, S. K., J. Cheh, L. Isaacs, D. Joseph-McCarthy, S. K. Choi, D. C. Pevear, G. M. Whitesides, and J. M. Hogle. 2001. A structurally biased combinatorial approach for discovering new anti-picornaviral compounds. Chem Biol 8:33-45. 33.Wang, J. R., Y. C. Tuan, H. P. Tsai, J. J. Yan, C. C. Liu, and I. J. Su. 2002. Change of major genotype of enterovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000. J Clin Microbiol 40:10-5. 34.Wimmer, E., C. U. Hellen, and X. Cao. 1993. Genetics of poliovirus. Annu Rev Genet 27:353-436. 35.Yan, J. J., J. R. Wang, C. C. Liu, H. B. Yang, and I. J. Su. 2000. An outbreak of enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J Clin Virol 17:13-22.
|